Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,769 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06540326RecruitingPhase 2
Second-line therapy for advanced colorectal cancer
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
Hangzhou, ZhejiangAges 18–75 - NCT06506643RecruitingPhase 1/Phase 2
Study of KLS-1 for solid tumors and CLL
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
KropyvnytskyiAges 18 years+ - NCT06504732RecruitingPhase 2/Phase 3
IAH0968 plus CAPEOX for HER2-positive gastric cancer
This trial tests a new drug (IAH0968) combined with chemotherapy (CAPEOX) for people with HER2-positive stomach or gastroesophageal junction cancer that has not been treated before or has spread.
Harbin, HeilongjiangAges 18–75 - NCT06507930Recruiting
Supporting advanced breast cancer patients at home on hospice
This study explores how to best support people with advanced breast cancer who are receiving hospice care at home. It includes short video or phone check-ins and a survey to learn about your experience.
Boston, MassachusettsAges 18 years+ - NCT06500819RecruitingPhase 1
B7-H3 CAR T cells for relapsed solid tumors
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
Palo Alto, CaliforniaAges 2–30 - NCT06478693RecruitingPhase 1
Study of MT-303 for advanced liver cancer
This study tests a new drug called MT-303 for people with advanced liver cancer (HCC) or other cancers that produce a protein called GPC3. The drug is designed to target and attack the cancer cells. The trial is in an early phase, so it is looking at safety and how well the drug works.
Sydney, New South WalesAges 18 years+ - NCT06481592RecruitingPhase 2
Study of lifileucel for advanced endometrial cancer
This trial tests an experimental cell therapy called lifileucel, made from your own immune cells, for advanced endometrial cancer that has progressed after standard treatments. It aims to shrink tumors and slow the disease.
Phoenix, ArizonaAges 18–70 - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06465511Recruiting
Supportive clinic for advanced or metastatic cancer
This study offers a supportive care clinic for people with advanced or metastatic cancer. The goal is to help manage symptoms and improve quality of life during treatment.
Hong KongAges 18 years+ - NCT06439771RecruitingPhase 2
Testing YL202 for advanced breast cancer
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06430437RecruitingPhase 3
Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06413953RecruitingPhase 1
Testing TQB3107 for advanced solid tumors
This trial is testing a new oral medication called TQB3107 for people with advanced solid tumors (cancer that has spread or cannot be removed). The study aims to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06405425RecruitingPhase 2
Study of BL-B01D1 and immunotherapy for advanced bladder cancer
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05807035RecruitingPhase 1
Personalized vaccine made from your tumor tissue
This Phase 1 trial tests a personalized (autologous) vaccine made from your own tumor tissue. It’s designed for people with advanced cancers who have already had at least one treatment and may still have options for getting tumor tissue for the vaccine.
Adelaide, South AustraliaAges Any age - NCT02155621Recruiting
Personalized gene testing to guide cancer treatment choices
This study uses gene testing on stored tumor tissue (and a blood sample) to help doctors recommend treatment options that may fit your tumor’s specific changes. It may also help avoid certain medicines and share your de-identified data with other researchers.
Vancouver, British ColumbiaAges 18–85 - NCT04678362RecruitingPhase 2
Maintenance treatment with talazoparib plus immunotherapy for bladder cancer
This trial tests whether continuing two medicines after your initial platinum chemotherapy can help keep your urothelial (bladder/urine tract) cancer from coming back or worsening. It is for people whose cancer shrank or stayed stable after chemotherapy and who cannot be cured with surgery or radiation.
AngersAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Fountain Valley, CaliforniaAges 18 years+ - NCT06342440Recruiting
Early detection of colon cancer and advanced polyps
This study aims to find colorectal cancer and advanced polyps (adenomas) earlier by looking at blood samples. Researchers hope a simple blood test might one day help detect colon cancer before it spreads.
Monrovia, CaliforniaAges 18 years+ - NCT06339619RecruitingPhase 2
Combination immunotherapy for advanced esophageal cancer after prior treatment
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Guangzhou, GuangdongAges 18–75 - NCT06332755RecruitingPhase 1
Study of LB-LR1109 alone and with atezolizumab for cancer
This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.
Fairfax, VirginiaAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,769 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.